Fish oil for cardiovascular health: study results conflict Print
Written by FHInews   
Thursday, 27 September 2018 00:00
Amarin share prices nearly quadrupled after the biopharmaceutical company's fish oil capsule showed dramatic benefits to heart patients in a clinical trial, according to a report posted to on 9.24.18 and written by Berkeley Lovelace, Jr. and Michelle Fox. Amarin says its capsule, Vascepa, significantly reduced the risk of serious cardiovascular events over a placebo in a trial of 8,179 statin-treated adults with elevated cardiovascular risk. View article>>

These results conflict with a study released over the summer that demonstrates no benefit from fish oil. See study>>

Last Updated on Friday, 28 September 2018 12:30